Intermediate dose of blood thinners works well for Covid patients than high or low dose: Study

New Delhi: An intermediate level of anticoagulation (blood thinning) had an 86 per cent probability of being more helpful than low or high dose anticoagulation in Covid patients, according to a new study.

The study was based on randomised clinical trial to test different levels of anticoagulation in more than 1,500 patients in India, Australia, New Zealand and Nepal,
The AustralaSian COVID-19 Trial (ASCOT) has pinpointed the most efficient level of blood thinning treatment needed for patients hospitalised with Covid, in the study which has been published in the New England Journal of Medicine Evidence and presented at the American Society for Hematology conference.

According to officials, patients in hospital with COVID-19 are at increased risk of blood clots (or thromboses), which in turn may contribute to development of organ failure.